Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03669809
Other study ID # 20180326
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date May 1, 2011
Est. completion date May 1, 2050

Study information

Verified date November 2021
Source Shandong Provincial Hospital
Contact Ling Gao
Phone +86 53168776910
Email gaoling1@medmail.com.cn
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The circadian regulation in mammals have been known for a long time. A special group of clock genes, organized in feedback loops, are responsible for the circadian regulation in both the SCN and peripheral organs. The central clock is mainly entrained by the light-dark cycle, while the peripheral ones in organs such as liver and intestine, are more influenced by the feeding-fasting cycles. The coordination of central and peripheral clocks is thought to be essential in the maintenance of physiological homeostasis.This study aim to investigate the association between biological rhythm and metabolism.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date May 1, 2050
Est. primary completion date May 1, 2050
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 30 Years
Eligibility Inclusion Criteria: - Male or female; - Aged of 18 to 30 years old; Exclusion Criteria: - Presence of pituitary/hypothalamic disorders, polycystic ovarian syndrome, thyroid disorders, hypertension, malignant tumor, cardiac insufficiency,hepatic or renal insufficiency, gastrointestinal disorders and acute infection; - Receiving psychotropic or hormonal medications including hormonal contraception and hormone therapies; - Taking lipid-lowering agents or hypoglycemic agents and other drugs that known to influence cardiovascular health; - Pregnancy or lactation women; - Obviously poor compliance.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
China Shandong Provincial Hospital Jinan Shandong

Sponsors (1)

Lead Sponsor Collaborator
Shandong Provincial Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary circadian rhythms of serum lipid levels (the change of serum lipid levels within 24 hours) Measured at baseline, and every 10 years during the 40-year follow-up period
Secondary circadian rhythms of gonadal hormone and gonadotropin(the change of gonadal hormone and gonadotropin within 24 hours) Measured at baseline, and every 10 years during the 40-year follow-up period
Secondary circadian rhythms of serum total bile acids(the change of serum total bile acids within 24 hours) Measured at baseline, and every 10 years during the 40-year follow-up period
Secondary change in urine metabolite Measured at baseline, and every 10 years during the 40-year follow-up period
Secondary change in intestinal flora Measured at baseline, and every 10 years during the 40-year follow-up period
Secondary change in sperm quality Measured at baseline, and every 10 years during the 40-year follow-up period
See also
  Status Clinical Trial Phase
Recruiting NCT05864833 - METabolism After Orthopedic Surgery
Completed NCT02235961 - Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects Phase 1
Completed NCT02918279 - Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity Phase 3
Completed NCT00978393 - A Trial to Assess the Effect of Liraglutide on Gastric Emptying in Healthy Obese Volunteers Phase 1
Completed NCT03661879 - Research Study of a New Medicine (NNC9204-1706) in People With Overweight or Obesity Phase 1
Completed NCT05024032 - A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN) Phase 3
Completed NCT02568306 - A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses and Multiple Doses of NNC0165-1562 in Overweight to Obese But Otherwise Healthy Subjects Phase 1
Completed NCT00781937 - Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance Phase 3
Completed NCT03223493 - Awareness, Care & Treatment in Obesity Management (ACTION) Study
Completed NCT03308721 - Research Study Investigating Study Medicine (NNC9204-1177) for Weight Management in People With Overweight or Obesity Phase 1
Completed NCT02941042 - A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-1177 in Subjects Being Overweight or With Obesity. Phase 1
Completed NCT02453711 - Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus Phase 2
Completed NCT02527200 - Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome Phase 3
Completed NCT02958085 - Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Subjects With Obesity or Overweight Phase 1
Terminated NCT00665665 - Safety, Efficacy, Tolerability and Pharmacokinetics of NNC 0070-0002-0182 in Overweight or Obese Male and Female Volunteers Phase 1
Completed NCT04156165 - The Effect of High vs. Moderate Protein Consumption on Human Health N/A
Completed NCT02079870 - Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo Phase 1
Completed NCT03095807 - Investigation of Single Ascending Doses of NNC9204-1706 in Male Subjects Being Overweight or With Obesity Phase 1
Recruiting NCT05785221 - Lifestyle Intervention on Metabolic Homeostasis N/A
Recruiting NCT06327854 - NUtrition and ORal Health in Orthopaedic Surgery